ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients

Screening for anaplastic lymphoma kinase ( ) rearrangements is a very important process in treatment decision making for advanced non-small-cell lung cancer (NSCLC). Although fluorescent in situ hybridization (FISH) is considered the universally accepted reference standard, it is associated with tec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacogenomics and personalized medicine Jg. 11; S. 147 - 155
Hauptverfasser: Uruga, Hironori, Mino-Kenudson, Mari
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New Zealand Dove Medical Press Limited 01.01.2018
Taylor & Francis Ltd
Dove Medical Press
Schlagworte:
adenocarcinoma
ALK (D5F3) CDx
Anaplastic lymphoma kinase gene (ALK)
Antibodies
Cancer therapies
Carboplatin
Chemotherapy
Comparative analysis
Crizotinib
Cytogenetics
D5F3 antibody
Diagnosis
Immunohistochemistry
Kinases
Lung cancer
Lung cancer, Non-small cell
Lymphatic system
Lymphoma
Medical equipment and supplies industry
Medical test kit industry
Metastasis
Mutation
Non-Hodgkin's lymphomas
non-small cell lung cancer
Non-small cell lung carcinoma
Pathology
Pemetrexed
Proteins
Review
Tumors
Viral antibodies
United States
Japan
United States > US
ALK (D5F3) CDx
adenocarcinoma
D5F3 antibody
anaplastic lymphoma kinase gene ALK
non-small-cell lung cancer
ISSN:1178-7066, 1178-7066
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Screening for anaplastic lymphoma kinase ( ) rearrangements is a very important process in treatment decision making for advanced non-small-cell lung cancer (NSCLC). Although fluorescent in situ hybridization (FISH) is considered the universally accepted reference standard, it is associated with technical difficulties and high costs that have made global implementation of this assay challenging. Conversely, ALK immunohistochemistry has shown high sensitivity and specificity compared to FISH and other molecular assays and is more cost-effective. In fact, the ALK (D5F3) CDx immunohistochemistry assay was approved by the US Food and Drug Administration as a standalone test for rearrangements in lung cancer in 2015. In this review, we will discuss the overview of rearrangements in NSCLC, various testing methods for rearrangements, and the details of immunohistochemistry for ALK, in particular one with the ALK antibody clone D5F3.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1178-7066
1178-7066
DOI:10.2147/PGPM.S156672